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Abstract
The g-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in vertebrate CNS. At GABAergic synapses, a high-affinity
transporter exists, which is responsible for GABA reuptake and release during neurotransmission. GABA transporter activity depends on
21the phosphorylation /dephosphorylation state, being modulated by Ca /calmodulin-dependent protein phosphatase 2B (calcineurin).
21Aluminium is known to interfere with the Ca /calmodulin signalling pathway. In this work, we investigate the action of aluminium on
GABA translocation mediated by the high-affinity transporter, using synaptic plasma membrane (SPM) vesicles and synaptosomes
21isolated from brain cortex. Aluminium completely relieved Ca downregulation of GABA transporter, when mediating uptake or release.
21Accordingly, aluminium inhibited Ca /calmodulin-dependent calcineurin activity present in SPM, in a concentration-dependent manner.
The deleterious action of aluminium on the modulation of GABA transport was ascertained by comparative analysis of the aluminium
21
effect on GABA uptake and release, under conditions favouring SPM dephosphorylation (presence of intracellular micromolar Ca ) or
21phosphorylation (absence of Ca and/or presence of W-7, a selective calmodulin antagonist). In conclusion, aluminium-induced relief of
21Ca modulatory action on GABA transporter may contribute significantly to modify GABAergic signalling during neurotoxic events in
response to aluminium exposure.
  2003 Elsevier Inc. All rights reserved.
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1 . Introduction suggest the aluminium-induced impairment of particular
chemically coded neuronal populations [8–10]. However,
The blooming industrialized society increases alumin- the explanation for the development of aluminium deleteri-
ium bioavailability as a result of continued acidification of ous effects seems to be founded in the imbalance of
the environment. Aluminium salts are used in the pharma- ubiquitous cellular processes [2,11–20]. Over the past
ceutical industry, and they are generally used as flocculants three decades, aluminium has been shown to interfere with
in treating drinking water. Nowadays, aluminium is recog- the main steps of the neurotransmission event (synthesis,
nised as a neurotoxic agent [1,2]. During the last 30 years, storage, release, postsynaptic reception and inactivation of
the emergence of extensive evidence on aluminium poison- neurotransmitters), which takes place at the synapse.
ing has demonstrated the adverse affect of aluminium in Aluminium could modify the homeostasis of neurotrans-
inducing memory impairment, personality changes and mitters in presynaptic nerve terminals in several ways: (i)
dementia in humans [3–6]. Additionally, bioavailable by chelating neurotransmitter molecules [8,10,21,22]; (ii)
aluminium seems to be associated with neurological by modifying the activity of enzymes responsible for
deterioration during aging [7]. transmitter synthesis and degradation [23–28]; and (iii) by
The mechanisms by which aluminium exerts its neuro- compromising carrier-mediated neurotransmitter uptake
toxic action remain poorly understood. Current hypotheses [21,29–31]. Although, no direct effects of aluminium on
neurosecretion machinery have previously been reported,
21the putative deleterious action of aluminium on Ca -
dependent, depolarisation-evoked neurotransmitter ex-
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aluminium action on neurotransmitter postsynaptic recep- 2 .2. Isolation of synaptic plasma membrane vesicles and
tors [15,36–38]. synaptosomes
Previous research highlighted the hypothesis that alu-
minium may exert its toxic properties by interacting with The SPM vesicles were isolated from sheep brain
21
calmodulin (CaM), a ubiquitous regulatory protein in Ca cortex, as previously described [61]. After homogenisation
signalling pathways of all eukaryotic cells, that plays a of the brain cortical grey matter, the homogenate was
pivotal role in the regulation of stimulus-secretion coupling centrifuged at 9003g during 10 min, and the resulting
in nerve cells [39–42]. Several investigators clearly dem- supernatant was centrifuged at 10 0003g during 20 min.
onstrated that aluminium bound to calmodulin leads to the After lysis of the pellet material (crude synaptosomal
loss of calmodulin ability to interact with target proteins, fraction) in hypotonic alkaline medium, followed by
producing impairment of its regulatory role [18,43–45]. In successive centrifugations at 80003g (10 min) and
fact, aluminium changes the conformation of calmodulin 35 0003g (30 min), the resuspended pellet was cen-
21[18,45–52], thus preventing the Ca -induced transition trifuged through a discontinuous Dextran T500 gradient for
between conformational states that are associated with the 2 h at 23 0003g. The collected bands, containing the SPM,
regulatory function of this protein. The protein phospha- were diluted and centrifuged at 35 0003g during 30 min.
tase 2B (calcineurin), a key enzyme involved in the Then, the pelleted vesicles were resuspended (5 mg
1
regulation of neurotransmission, is dependent on the protein /ml) and loaded with K by incubating 30 min, at
21 21presence of Ca and calmodulin (Ca /CaM) in order to 30 8C, in a medium containing 0.1 mM MgSO and 1504
modulate the activity of multiple proteins at the synapse mM MES-potassium salt at pH 6.5. After the incubation
[39–42,53–55]. period, SPM vesicles were centrifuged 30 min at 35 0003
Over the past few years, we have been reporting the g and the pellet was resuspended in the same buffer to give
involvement of calcineurin on the regulation of carrier- a final concentration of about 20 mg protein /ml. Finally,
mediated translocation of GABA, the major inhibitory the preparation was divided into several aliquots, which
21
neurotransmitter in the adult mammalian CNS. Ca / were frozen in liquid nitrogen and stored at 270 8C. When
CaM-dependent calcineurin activity seems to be respon- required, the SPM vesicles were thawed at room tempera-
sible for the downregulation of GABA transporter, either ture.
when mediating its release or reuptake from the synaptic The synaptosomes were prepared according to the
´cleft [56–60]. In the present study, we investigate the method of Hajos [62]. Male Wistar rats were sacrificed by
effect of aluminium on the carrier-mediated GABA trans- decapitation and the brains were removed. The brain
port across the synaptic plasma membrane (SPM) and on cortices were rapidly dissected, homogenized in 9 volumes
21its regulation by Ca /CaM-dependent calcineurin activa- of ice-cold 0.32 M sucrose buffered with 10 mM Hepes–
21tion. We found that aluminium inhibits Ca /CaM-depen- Tris (pH 7.4) and centrifuged at 15003g for 10 min. The
21dent calcineurin activity and completely reverts the Ca - supernatant was centrifuged at 90003g for 20 min and the
induced inhibition of both GABA uptake and release by pellet was resuspended in the homogenisation solution.
SPM vesicles. Finally, we verified whether aluminium- The crude synaptosomal fraction was layered over 0.8 M
21induced relief of Ca modulatory action on GABA sucrose and centrifuged at 90003g for 30 min. Then, the
transporter occurs under more physiological conditions, by synaptosomal enriched fraction, collected from the 0.8 M
using a preparation of intact nerve terminals (synapto- sucrose layer, was 2-fold diluted and centrifuged at
somes). 20 0003g for 30 min. The final pellet was resuspended in
0.32 M sucrose and 10 mM Hepes–Tris (pH 7.4) at a final
concentration of about 8 mg protein /ml. All procedures
2 . Materials and methods were performed at 0–4 8C.
The protein content of both subcellular fractions was
2 .1. Reagents measured according to the method developed by Gornall et
al. [63], using bovine serum albumin as a standard.
3 3The 4-amino-n-[2,3- H]butyric acid ([ H]GABA), with
a specific activity of 81.0 Ci /mmol, was purchased from 2 .3. Measurement of protein phosphatase 2B
Amersham. RII phosphopeptide was obtained from (calcineurin) activity of synaptic plasma membrane
Biomol. W-7 and ionomycin were supplied by Calbioch-
em–Novabiochem. Malachite green, cyclosporin A, The measurement of calcineurin activity was performed
aminooxyacetic acid (AOAA) and AlCl were obtained by using RII phosphopeptide as specific substrate. The3
from Sigma–Aldrich. Aluminium trials were performed by utilization of RII phosphopeptide was performed with
adding aliquots (|4 ml) of AlCl from freshly made stock modification of the method described by Martin et al. [64].3
solutions to reaction media, immediately before the begin- SPM vesicles (0.5 mg protein /ml) were incubated, at
ning of the incubation period. The filters used for retention 30 8C, in 170 ml of 50 mM EGTA and 10 mM Hepes–Na
of subcellular fractions were obtained from Whatman. (pH 7.4). After 2 min, the reactions were initiated by
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adding 5 mM RII phosphopeptide and, at various time min of superfusion, the medium was quickly substituted
1intervals, they were stopped with 30 ml of 2.5 M H SO . for K depolarisation medium (150 mM KCl, 50 mM2 4
Subsequently, the malachite green reagent (800 ml) was EGTA and 10 mM Hepes–K at pH 7.4). Fractions were
added, and the suspensions were mixed and allowed to sit collected every minute directly into scintillation vials. The
for 15 min. The absorbance changes were measured at 660 radioactivity was measured as described above for the
3
nm in a spectrophotometer (Perkin-Elmer Lambda 14P). uptake assays. The values for [ H]GABA release by SPM
The malachite green reagent was prepared as described by vesicles were expressed as dpm/fraction or as arbitrary
Harder et al. [65]. units (a.u.) that were calculated using the following
equation:
32 .4. Measurement of [ H]GABA uptake by synaptic x
plasma membrane vesicles and synaptosomes 3 3 3GABA released (a.u.)5E[( H 2 H ) / H ] dtx b b
a3The uptake of [ H]GABA by SPM vesicles and synapto-
3
where H corresponds to the dpm counted in fraction xsomes was measured isotopically as described elsewhere x
33 and H corresponds to the extrapolated basal dpm level in[61,66]. The [ H]GABA uptake reactions were carried out b
the fraction x(a).at 30 8C in the presence of 0.5 mM GABA supplemented
3 GABA release values were calculated by using Originwith [ H]GABA (0.25 mCi/ml). The reactions were
computer program, and J (maximal translocation ve-initiated by adding SPM vesicles (final concentration 0.5 max
locity) corresponds to the slope of the resulting curves.mg protein /ml) to the reaction media or by the addition of
3[ H]GABA to media containing synaptosomes (final con-
2 .6. Treatment of the datacentration 0.5 mg protein /ml). Unless otherwise indicated
in the legends of the respective figures, uptake reactions
All results were treated statistically with Origin com-were performed in media containing 150 mM NaCl, 10
puter program. Results are presented as means6S.E.M. ofmM Hepes–Na (pH 7.4), 50 mM EGTA and 2 mM
the number of experiments indicated in the figures. Statisti-ionomycin (SPM vesicle medium), or containing 128 mM
cal significance was determined by means of an unpairedNaCl, 1.2 mM MgCl , 5 mM KCl, 10 mM glucose, 10 mM2
two-tailed Student’s t-test or by analysis of varianceAOAA, 10 mM Hepes–Na (pH 7.4), 100 mM EGTA and 2
(ANOVA) followed by Bonferroni post-hoc test. A P valuemM ionomycin (synaptosome medium). The reactions were
,0.05 was considered significant.stopped by rapid filtration of 500-ml aliquots through
glass-fiber filters (Whatman GF/B), prewashed with 5 ml
of 150 mM NaCl or 320 mM sucrose, 10 mM Tris–HCl
3 . Results(pH 7.4) and 100 mM EGTA for SPM vesicle and
synaptosomal preparations, respectively. The filters were
213 .1. Aluminium effect on Ca /calmodulin-dependentthen washed with 10 ml of the same medium and they
protein phosphatase 2B (calcineurin) activitywere plunged in scintillation cocktail (Universol ES) for
further radioactivity measurement by liquid scintillation
213 Calcineurin, the most important Ca /CaM-dependentspectrometry. The values for [ H]GABA uptake were
protein phosphatase activity involved in the regulation ofexpressed as pmol /mg protein per min after subtraction of
presynaptic events during neurotransmission [41,67], wasblank values obtained by filtering aliquots of reaction
shown to be widely distributed in various organelles withinmedium containing 0.5 mM GABA supplemented with
3 neurons (from the soma to dendrites), including the plasma[ H]GABA (0.25 mCi/ml).
membrane [41,42].
3 In previous reports we have demonstrated that SPM2 .5. Measurement of [ H]GABA release by synaptic
21
vesicles exhibit Ca /CaM-dependent calcineurin activity,plasma membrane vesicles
21
reaching maximal levels by raising free Ca concen-
3 trations up to few micromolar [58]. Therefore, we investi-The release of [ H]GABA from SPM vesicles was
21gated whether aluminium could interfere with the Ca /followed by the superfusion technique previously de-
CaM-dependent activity of calcineurin. Fig. 1 shows thescribed [61]. The SPM vesicles were loaded with
3 activity of this enzyme in the presence of increasing AlCl[ H]GABA during 2 min in the presence of 0.5 mM 3
21GABA as described above, except that ionomycin was concentrations, in the absence or in the presence of Ca
21 21
absent. Using a peristaltic pump, the loaded SPM vesicles ions. Under Ca concentration (10 mM free Ca ) that
were spread on glass microfiber filters (Whatman GF/B) assures maximal activation of calcineurin (|10 nmol P /i
mounted in Millipore metal 13 mm Swinnex filter holders. mg protein per 50 min), aluminium affected significantly Pi
21The filters were continuously washed with a medium production, in a dose-dependent manner. In fact, Ca /
containing 150 mM NaCl, 50 mM EGTA and 10 mM CaM-dependent calcineurin activity was completely
Hepes–Na (pH 7.4), at a flow rate of 0.31 ml /min. After 8 abolished in the presence of 300 mM AlCl . It is notewor-3
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 CaM-dependent calcineurin activity, maximal uptake of
GABA and its maximal release rate by |50 and |65%,
respectively [56,57,59].
Fig. 2 shows the time course of GABA uptake mediated
1by its high-affinity Na -dependent GABA transport sys-
tem, in the absence and in the presence of 300 mM AlCl .3
As it can be observed, aluminium produced a statistical
non-significant decrease of the initial rate of accumulation
3
and of the maximal uptake of [ H]GABA (after 2–3 min
incubation). However, a 30% reduction of the amount of
3[ H]GABA retained by SPM vesicles could be observed
when incubation period was extended up to 8 min. This
effect should be the result of aluminium-induced altera-
tions of membrane physical properties rather than a direct
action on the GABA transport system, since GABA uptake
by SPM vesicles is driven by artificially imposed ionic
gradients [58,68].
21The first evidence that aluminium jeopardizes the CaFig. 1. Calcineurin activity as a function of aluminium concentration. The
modulatory action on GABA transport derives from thesynaptic plasma membrane (SPM) vesicles (0.5 mg protein /ml) were
21
observation that Ca -induced inhibition of GABA uptakeincubated in a medium containing 10 mM Hepes–Na (pH 7.4), 50 mM
EGTA and 5 mM RII phosphopeptide as specific calcineurin substrate. by SPM vesicles was totally relieved by 300 mM AlCl3
21The reactions were carried out for 50 min in the presence of increasing (Fig. 3). As we can see, the addition of Ca to the
AlCl concentrations (0–300 mM). The reactions were stopped with 303 reaction medium in the presence of ionomycin, a specific
ml of 2.5 M H SO , and inorganic phosphate (P ) was quantified as2 4 i 21 3
21 Ca ionophore, reduced the amount of [ H]GABA ac-described in Section 2. The Ca /CaM-dependent calcineurin activity
cumulated by SPM vesicles from 141 to 79 pmol /mgwas determined from the amount of P produced in the presence of 10 mMi
21free Ca by subtracting the amount of P produced in the absence of protein. This reduction is in accordance with the previous-i
21added CaCl . The insert represents the calcineurin activity in the absence2 ly reported effect of intravesicular Ca on GABA uptake21(s–s) or in the presence of 10 mM free Ca (•–•) as a function of 21[56,57,59]. In contrast, Ca -induced decrease of GABAAlCl concentration. Vertical bars denote S.E.M. of the mean value of at3
uptake did not occur when 300 mM AlCl was present inleast six separate determinations. 3
uptake medium, corresponding to a total prevention of the
21intravesicular Ca effect by aluminium.
thy that even when calcineurin activation could be attribu-
21
 ted to contaminating levels of Ca in the nanomolar range
(|7 nmol P /mg protein per 50 min), aluminium was ablei
to decrease P production down to |6 nmol P /mg proteini i
per 50 min, which corresponds to values obtained in the
presence of cyclosporin A, a selective calcineurin inhibitor
(|6 nmol P /mg protein per 50 min).i
21These results clearly show that Ca /CaM-dependent
calcineurin activity of SPM is inhibited by aluminium, in a
concentration-dependent manner, and maximal inhibition
is reached in the presence of 300 mM AlCl . Therefore,3
further experiments, addressing aluminium effect on
GABA transport in brain cortex nerve terminals, were
performed in the presence of 300 mM AlCl , since total3
inhibition of Ca/CaM-dependent calcineurin activity is
required to clearly demonstrate the effect of aluminium-
21induced impairment of Ca modulatory action on GABA
transport.
3Fig. 2. Effect of aluminium on [ H]GABA uptake by SPM vesicles. SPM
213 .2. Aluminium effect on Ca /calmodulin regulation of vesicles (0.5 mg protein /ml) were incubated in a medium containing 150
mM NaCl, 50 mM EGTA, 10 mM Hepes–Na (pH 7.4) and 0.5 mMcarrier-mediated GABA uptake and release by SPM
3[ H]GABA, in the absence (s–s) or in the presence of 300 mM AlCl3vesicles (•–•). The reactions were stopped by filtering 0.5 ml aliquots and the
filters radioactivity was measured as described in Section 2. Vertical bars21Intravesicular Ca , at micromolar concentrations, was denote S.E.M. of at least six independent experiments. *P,0.01,
21previously found to decrease, via stimulation of Ca / statistically significant from control value.
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21 3 21 3Fig. 3. Aluminium relieves the Ca -induced [ H]GABA uptake inhibi- Fig. 4. Aluminium relieves the Ca inhibitory effect on [ H]GABA
tion in SPM vesicles. Experimental conditions were the same as described uptake by SPM vesicles: sensitivity to W-7 (calmodulin antagonist).
in the legend of Fig. 2, except that the assays were performed for 2.5 min Experimental conditions were the same as described in the legend of Fig.
21in the presence of 2 mM ionomycin (a specific Ca ionophore). The 2. The reactions were carried out for 2.5 min in the absence and in the
21
reactions were carried out in the absence or in the presence of 10 mM free presence of 10 mM free Ca , under various experimental conditions
21Ca . Control condition (absence of AlCl ), white bar; presence of 300 (reaction medium supplemented with 2 mM ionomycin, 2 mM ionomycin3
mM AlCl , black bar. Vertical bars denote S.E.M. of four independent plus 300 mM AlCl , 2 mM ionomycin plus 10 mM W-7 or 2 mM3 3
experiments. *P,0.02, statistically significant from control value. ionomycin plus 300 mM AlCl and 10 mM W-7). Bars show the3
21percentage of inhibition by Ca in the absence (white bar) or in the
presence of 300 mM AlCl (black bar).Vertical bars denote S.E.M. of four321As previously reported, Ca -induced inhibition of independent experiments. *P,0.01, statistically significant from control
value.GABA uptake by SPM vesicles can be relieved by W-7, a
specific calmodulin antagonist, and this is also observed in
our experimental conditions (Fig. 4). In fact, the inhibitory slightly increased when SPM vesicles were superfused
21
effect of Ca on GABA uptake (56%) was found to be with depolarisation medium containing 300 mM AlCl . It3
almost completely prevented by either aluminium (Figs. 3 should not be ruled out that aluminium could neutralize
and 4) or W-7 (Fig. 4). Furthermore, concomitant presence membrane-surface charges of sialic acid molecules and
of 300 mM AlCl and 10 mM W-7 during GABA uptake cause rigidification of SPM [70–74], which may contribute3
reaction did not show any additive effects. These results in improving the translocation capacity of the high-affinity
are in line with those shown in Fig. 1, where total GABA transporter [75,76]. However, the statistical non-
21inhibition of Ca /CaM-dependent calcineurin activity by significant aluminium stimulatory effect (19%) is probably
300 mM AlCl was observed. attributed to the enhancement of GABA translocation rate3
1Fig. 5 shows the effect of aluminium on K de- by its transport system, due to aluminium inhibition of
3 21polarisation-induced [ H]GABA release from SPM vesi- Ca /CaM-dependent calcineurin activity in presence of
21
cles, which corresponds to neurotransmitter translocation residual Ca in the nanomolar range (Fig. 1).
21in the backward direction by the GABA transport system Aluminium-induced relief of the Ca inhibitory effect
3[57,58,69]. SPM vesicles were actively loaded with on [ H]GABA release is clearly shown in Fig. 6.
3 3 1[ H]GABA during 2 min, and then were superfused with [ H]GABA released from SPM vesicles in response to K
21150 mM NaCl, 50 mM EGTA and 10 mM Hepes–Na (pH depolarisation in the presence of Ca was 1.2 a.u. (Fig.
17.4) during 8 min, to remove the non-accumulated 6A), representing a 63% decrease when compared to K
3 3[ H]GABA. Fig. 5 represents a typical experiment, show- depolarisation-induced release of [ H]GABA in the ab-
21ing the late 4 min of NaCl washout of non-accumulated sence of Ca (3.2 a.u.). Conversely, it was observed that
3[ H]GABA, followed by induction of carrier-mediated in presence of 300 mM AlCl (Fig. 6B), the maximal3
3 3[ H]GABA release due to substitution of the superfusion translocation velocity (J ) of [ H]GABA release inmax
1 1
medium by similar medium, where Na was replaced by response to K depolarisation of SPM reached maximal
1 21K . A massive GABA efflux from the vesicles occurred values (1.1 a.u. /min) even when 10 mM Ca was added
1during 4 min. The time course of K depolarisation- to the superfusion medium. Actually, when 300 mM AlCl3
3 1induced release of [ H]GABA from SPM vesicles can be was introduced in K depolarisation media, both J andmax
3plotted in a cumulative curve of arbitrary units (a.u.) as total amount of [ H]GABA released from SPM vesicles
shown in the insert of Fig. 5. It can be seen that reached maximal values, which correspond to a 3-fold
3 1[ H]GABA release triggered by K depolarisation was increase of the above mentioned parameter values when
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 3 .3. Aluminium effect on GABA uptake by synaptosomes
The study of aluminium effect on GABA transport
greatly benefited from SPM vesicle preparation, since ionic
gradients were artificially imposed, constituting the sole
driving force for GABA transport. If SPM vesicle prepara-
tion facilitated identifying the underlying mechanism by
which aluminium interferes with this transport system, it
appears quite relevant to bring to light whether the
21disruption of Ca modulatory action on GABA transport
by aluminium can occur under more physiological con-
ditions. Thereby, aluminium effect on GABA uptake by
synaptosomes was studied, since this subcellular fraction
consists of intact nerve terminals.
Fig. 8 shows that when synaptosomes were incubated in
3the presence of 300 mM AlCl , the amount of [ H]GABA3
taken up during 15 min was reduced from 321 to 198
3 pmol /mg protein. This observation, aluminium-inducedFig. 5. Effect of aluminium on [ H]GABA release by SPM vesicles.
3 3SPM vesicles (0.5 mg protein /ml), actively loaded with [ H]GABA decrease (38%) of [ H]GABA uptake by synaptosomes, is
3(incubation at 30 8C, during 2 min, with [ H]GABA 0.5 mM, 150 mM in contrast to the lack of effect of aluminium on
NaCl, 50 mM EGTA and 10 mM Hepes–Na, at pH 7.4), were superfused 3[ H]GABA uptake by SPM vesicles (Fig. 2), but it is induring 8 min with 150 mM NaCl, 50 mM EGTA and 10 mM Hepes–Na
3 agreement with previous reports by other investigators(pH 7.4), as described in the text. Then, [ H]GABA release from SPM
[2,21,29–31,77–80]. In fact, it was hypothesised thatvesicles was induced by replacement of the superfusion medium with
1 1different superfusion media buffered with 10 mM Hepes–Na (pH 7.4) (Na /K )-ATPase inhibition by aluminium could account
and containing 50 mM EGTA plus 150 mM KCl (s–s), plus 150 mM for the reduced accumulation of neurotransmitters in the
KCl and 300 mM AlCl (•–•), plus 150 mM NaCl (^–^) or plus 1503 presence of aluminium, by compromising the magnitude of
mM NaCl and 300 mM AlCl (m–m). The results are expressed in3 1the Na gradient and of membrane polarization state todpm/fraction and correspond to a representative experiment. Insert shows
1 3 which GABA transport is dependent on [68,81]. In thisthe K depolarisation-induced release of [ H]GABA (superfusion with
3media containing 150 mM KCl) in the absence (s–s) or in the presence context, the observed aluminium effect on [ H]GABA
of 300 mM AlCl (•–•). Values represent the integrated area of the3 uptake by synaptosomes was compared with that of3
released [ H]GABA as arbitrary units per minute, defined in Section 2. 1 1
ouabain, a selective inhibitor of the (Na /K )-ATPaseVertical bars denote S.E.M. of at least six independent experiments. (Fig. 8). The presence of 50 mM ouabain, which inhibits
1 1the (Na /K )-ATPase by |70% (data not shown), in the
1
compared to those obtained in response to K depolarisa- incubation medium produced a decrease (69%) of the total
21 3tion in the presence of 10 mM Ca and absence of amount of [ H]GABA taken up by synaptosomes. Further-
aluminium. These results suggest an increased transport more, in the presence of both 300 mM AlCl and 50 mM3
3
efficiency due to aluminium impairment of intravesicular ouabain, the extension of reduction of [ H]GABA uptake
21Ca -induced reduction of GABA transport across SPM, remained almost unaltered, which seems to reflect a
shown to act by decreasing J (Fig. 6A and [59]). restrained inhibitory action of aluminium on the GABAmax
1In order to investigate the involvement of calmodulin in uptake by synaptosomes via the inhibition of the (Na /
21 1
aluminium relief of Ca -induced inhibition of GABA K )-ATPase activity.
1 3
release in response to K depolarisation in SPM, we Fig. 9 shows the effect of 300 mM AlCl on [ H]GABA3
assessed the effect of the calmodulin antagonist, W-7. Fig. uptake by synaptosomes under conditions, which favour
217 shows that W-7 did not significantly modify either J Ca modulatory action on the GABA transport system. Itmax
21
or total amount of GABA released observed when 300 mM is clear that 10 mM free Ca , in the presence of
3AlCl was presented in superfusion media. Either the ionomycin, notably reduced the amount of [ H]GABA3
presence of aluminium, or aluminium and W-7, allowed taken up by synaptosomes from 278 to 227 pmol /mg
achieving release parameters (J and total GABA re- protein, which is in accordance with the downregulatorymax
21leased) values close to those obtained in control experi- action of intravesicular Ca previously observed when
1 21
ments (K depolarisation in the absence of Ca ). SPM vesicles were used (Fig. 3). Accordingly, when 300
The results indicate that aluminium stimulation of mM AlCl was present in the incubation medium, alu-3
1 21 3GABA uptake and K depolarisation-induced release by minium relieved Ca modulatory action on [ H]GABA
21SPM vesicles occurs, when intravesicular Ca concen- transport by synaptosomes (increasing the amount of
3trations are in micromolar range, and the underlying [ H]GABA taken up during 15 min from 227 to 262
21
mechanism seems to involve inhibition of the Ca /CaM- pmol /mg protein) (Fig. 9).
dependent calcineurin activity. The above results suggest that the modulation of GABA
J.M. Cordeiro et al. / Journal of Inorganic Biochemistry 97 (2003) 132–142138
 
1 3 21Fig. 6. Inhibition of K depolarisation-induced [ H]GABA release by Ca from SPM vesicles (A) and relieve by aluminum (B). The assays were
3performed as described in the legend of Fig. 5. The release of [ H]GABA from SPM vesicles was performed in the absence (A) or in the presence of 300
1
mM AlCl (B), and was induced by superfusion with K depolarisation medium (150 mM KCl, 50 mM EGTA and 10 mM Hepes–Na, at pH 7.4) in the3
21 3
absence (s–s) or in the presence of 10 mM free Ca (•–•). The maximal velocities of [ H]GABA release are represented by J . Values represent themax
3 3integrated area of the released [ H]GABA as arbitrary units per min. Inserted histograms represent the total amount of [ H]GABA released under the
different experimental conditions. Vertical bars denote S.E.M. of at least six independent experiments. *P,0.01, statistically significant from control value.
 
 
3Fig. 8. Effect of aluminium on [ H]GABA uptake by synaptosomes.
21 1 Synaptosomes (0.5 mg protein /ml) were equilibrated during 2 min, atFig. 7. Aluminium relieves the Ca inhibitory effect on K de-
3 30 8C, in incubation medium containing 128 mM NaCl, 1.2 mM MgCl , 5polarisation-induced [ H]GABA release from SPM vesicles: sensitivity to 2
mM KCl, 10 mM glucose, 10 mM AOAA, 100 mM EGTA and 10 mMW-7 (calmodulin antagonist). The assays were performed as described in
3 Hepes–Na (pH 7.4), in the absence (s–s) or in the presence of 300 mMthe legend of Fig. 5. The release of [ H]GABA from SPM vesicles was
1 AlCl (•–•), 50 mM ouabain (^–^) or 300 mM AlCl and 50 mMinduced by superfusion with K depolarisation medium (150 mM KCl, 3 3
3
ouabain (m–m). The reactions were started by adding [ H]GABA (final50 mM EGTA and 10 mM Hepes–Na, at pH 7.4) containing 10 mM free
21 concentration 0.5 mM), and were stopped by filtering 0.5 ml aliquots asCa , 300 mM AlCl in the absence (s–s) or in the presence of 10 mM3
1 described in Section 2. Vertical bars denote S.E.M. of at least fiveW-7 (•–•). K depolarisation-induced release (^–^) is plotted as
3 independent experiments.reference values. The maximal velocities of [ H]GABA release are
represented by J . Values represent the integrated area of the releasedmax
3[ H]GABA as arbitrary units per min. Inserted histograms represent the
3total amount of [ H]GABA released under the different experimental 21
1 transport system by Ca /CaM-dependent calcineurin
conditions (absence of W-7, white bar; presence of W-7, black bar; K
activation occurs in intact nerve terminals, and aluminiumdepolarisation, grey bar). Vertical bars denote S.E.M. of at least six
independent experiments. seems to interfere with this modulatory mechanism even
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 speciation, bioavailability and relative toxicity of the
distinct forms of aluminium. The average aluminium levels
in human brain cortex ranges from 0.14 to 0.22 mg/kg
[86], and aluminium concentrations in brain are signifi-
cantly increased during aluminium intoxication, dementing
diseases and metabolic encephalopathies [5,78,87,88].
Interestingly, Srabanti and Chaudhuri [89] showed that
oral administration of AlCl (50 mg/kg per day during 403
days) to rats resulted in a 70% decrease in calcineurin
activity. This observation seems to support the physiologi-
cal relevance of the results reported in this work (Fig. 1),
21
suggesting that the relief of Ca modulatory action on
GABA transport by aluminium may occur during in vivo
aluminum exposure.
Aluminium was reported to inhibit 40–50% the uptake
of GABA, glycine, glutamate, choline, dopamine, norad-
renaline and 5-hydroxytryptamine by synaptosomal frac-
21 3Fig. 9. Aluminium relives the Ca -induced [ H]GABA uptake inhibi- tions isolated from distinct brain regions [2,21,29–31,77–
tion in synaptosomes. Synaptosomes (0.5 mg protein /ml) were equili- 80]. The previously reported inhibitory effects of alu-brated as described in the legend of Fig. 8, except that the assays were 1 1
minium were mainly attributed to decreased (Na /K )-performed for 15 min in the presence of 2 mM ionomycin. Bars show the
ATPase activity [29], rather than to direct interaction withamount of GABA taken up during 15 min in the absence or in the
21presence of 10 mM free Ca . Control condition (absence of AlCl ), neurotransmitter transporters. In fact, the transport systems3
white bar; presence of 300 mM AlCl , black bar. Vertical bars denote3 responsible for the uptake of those neurotransmitters are
S.E.M. of at least nine independent experiments. *P,0.01, statistically 1driven by the Na electrochemical gradient maintained by
significant from control value. 1 1the (Na /K )-ATPase [60,61,68,81,90–92]. In the present
3
work, the effect of aluminium on the [ H]GABA uptake
was studied by using SPM vesicles (Figs. 2–4) and
under conditions of partial disruption of ionic gradients synaptosomes (Figs. 8 and 9) isolated from brain cortex.
across SPM. As mentioned earlier, these presynaptic membrane frac-
tions are especially different with respect to the process
1
underlying formation of the Na electrochemical gradient
across plasma membrane. Ionic gradients are imposed
1 14 . Discussion artificially to SPM vesicles, whereas (Na /K )-ATPase is
the main enzyme activity responsible for generation and
1In accordance to the knowledge of the authors, this work maintenance of the Na electrochemical gradient in
represents the first experimental evidence that links the synaptosomes. Accordingly, we observed that aluminium
1
well-established effects of aluminium on calmodulin func- did not inhibit the uptake of GABA when the Na
tion [18,39–41,44–54] with the effect of aluminium on electrochemical gradient was imposed artificially (SPM
GABA transport in brain cortex nerve terminals. We have vesicles) whereas aluminium produced a |40% reduction
demonstrated that aluminium relieves the modulatory of the amount of GABA taken up by synaptosomes. These
21
action of Ca on GABA transporter, operating either in results are in agreement with the findings of Wong [30],
forward (uptake) or backward (release) directions (Figs. 3, which showed a 50% inhibition of GABA uptake by 316
216 and 9), which involves Ca /CaM/calcineurin signal- mM AlCl . Moreover, no alterations in the amount of3
ling pathway (Figs. 1, 4 and 7). The modulation of cellular GABA taken up by synaptosomes during the addition of
1 1
activities represents one of the major mechanisms respon- aluminium were observed, when the (Na /K )-ATPase
sible for coupling signals to cellular responses, which is activity was already partially inhibited by ouabain, a
1 1foremost important in neurotransmission. selective inhibitor of the (Na /K )-ATPase (Fig. 8).
Calcineurin is one of the most abundant proteins in the In addition to the effect of aluminium on neurotrans-
1 1brain, accounting for over 1% of total protein [82,83]. The mitter transport due to inhibition of (Na /K )-ATPase,
regulation of neurotransmitter release by calcineurin was the results reported suggest that aluminium can possibly
21highlighted in glutamatergic and GABAergic transmission. prevent the modulation of GABA transport by Ca (Figs.
Both uptake and release of these neurotransmitters are 3, 4, 6, 7 and 9).
reduced upon activation of calcineurin [84,85]. Extrapola- GABAergic transmission relies on the occurrence of a
tion of aluminium effects observed in in vitro experiments transient of GABA at the synaptic cleft, rising from sub-
to in vivo conditions is difficult because of chemical micromolar range to millimolar range and back down to
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,1 mM in about 1 ms [93,94]. The high-affinity GABA vestigation of the effects of aluminium on other neuro-
transporter present at SPM is responsible for the shaping of transmitter transport systems.
GABAergic tone, not only because it mediates reuptake of
GABA back to presynaptic terminals [95–97], but also
because it mediates the release of this neurotransmitter to 5. Notation
the synaptic cleft in response to depolarisation of SPM
[57,60,91,98–102]. Recently, it has been reported that AOAA, aminooxyacetic acid; CaM, calmodulin; GABA,
carrier-mediated release of GABA can occur in response to g-aminobutyric acid; J , maximal translocation velocity;max1
slight increases of K concentrations (few millimolar) in Mes, 2[N-morpholino]ethanesulfonic acid; SPM, synaptic
the extracellular space [60,91,99], especially under con- plasma membrane; W-7, N-(6-aminohexyl)-5-chloro-1-
ditions that favour a simultaneous reduction of the mag- naphthalene-sulfonamide hydrochloride1
nitude of Na electrochemical gradient [60,81,91]. It
seems that under resting conditions the high-affinity
GABA transporter operates near its equilibrium, and the
A cknowledgementsinstantaneous direction of fluxes will depend mainly on
GABA and ionic gradients across SPM, as well as on
˜ ˆThis research was supported by Fundac¸ao para a Cienciachanges in membrane potential. On the contrary, when an
e a Tecnologia (grants POCTI/BSE/46721/2002, BM/action potential reaches the presynaptic terminal, GABA is
20580/99 and BD/21343/99).released by both exocytosis and reversal of the carrier-
mediated GABA transport, thereby assuring massive re-
lease of GABA into the synaptic cleft, necessary for
GABAergic transmission [94]. Meanwhile, activation of R eferences
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